Claudia Bardoni, Thoracic Surgeon at IEO Istituto Europeo di Oncologia, shared a post on LinkedIn:
“Honored to share that our abstract accepted for presentation at the American Society of Clinical Oncology (ASCO) Annual Meeting 2026 is now available online.
This systematic review and meta-analysis investigates clinicopathologic and imaging predictors of pathologic complete response following neoadjuvant chemoimmunotherapy in resectable NSCLC.
Our findings identify PD-L1 expression, FDG-PET metabolic response, and nodal status as the most consistent predictors of treatment response, while also highlighting the need for more robust and externally validated predictive models in thoracic oncology.”
Other articles about ASCO on OncoDaily.